ABSTRACT
Objective Increasing evidence suggests that reactive astrocytes are associated with Alzheimer’s disease (AD). However, its underlying pathogenesis remains unknown. Given the role of astrocytes in energy metabolism, reactive astrocytes may contribute to altered energy metabolism. It is hypothesized that lactate, a glucose metabolite, is produced in astrocytes and subsequently shuttled to neurons as an energy substrate. This study aimed to examine alterations in brain lactate levels and their association with astrocytic activities in AD.
Methods 30 AD and 30 cognitively unimpaired (CU) subjects were enrolled. For AD subjects, amyloid and tau depositions were confirmed by positron emission tomography using [11C]PiB and [18F]florzolotau, respectively. Lactate and myo-inositol, an astroglial marker, in the posterior cingulate cortex (PCC) were quantified by magnetic resonance spectroscopy (MRS). These MRS metabolites were compared with plasma biomarkers, including glial fibrillary acidic protein (GFAP) as another astrocytic marker.
Results Lactate and myo-inositol levels were higher in AD than in CU (p < 0.05). Lactate levels correlated with myo-inositol levels (r = 0.272, p = 0.047). Lactate and myo-inositol levels were positively associated with the Clinical Dementia Rating sum-of-boxes scores (p < 0.05). Significant correlations were noted between myo-inositol levels and plasma GFAP and tau phosphorylated at threonine 181 levels (p < 0.05).
Interpretation We found high lactate levels accompanied by an increased astrocytic marker in the PCC in AD. Thus, impaired lactate shuttle of reactive astrocytes may disrupt energy regulation, resulting in surplus lactate levels. Myo-inositol and plasma GFAP may reflect similar astrocytic changes.
Competing Interest Statement
M.-R.Z., H.Sd., and M.H. hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672). All other authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This work was supported by AMED under Grant nos. JP22dk0207063 and JSPS KAKENHI JP19H01041. This study was also supported in part by AMED under Grant nos. JP18dm0207018, JP19dm0207072, JP18dk0207026, and JP19dk0207049, and JSPS KAKENHI Grant nos. JP16H05324, JP18K07543, and JP21K18268.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of National Institutes for Quantum Science and Technology gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
